BioSpace News Archive

Drug Development

Angion Ends Kidney Disease Trial while Novo Hits NASH Wall

Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.

June 30, 2022
·
3 min read
·
Alex Keown
Drug Development

FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis

The FDA’s decision came after researchers found cases of drug-induced liver injury in some patients. Tolebrutinib is being evaluated for relapsing types of MS, MG, nrSPMS, and PPMS.

June 30, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Innate’s Cancer Therapeutics are Reaching New Clinical Heights

Many of Innate Pharma’s cancer-fighting products are making clinical progress. BioSpace spoke with the company’s head of product portfolio strategy and business development, Yannis Morel, Ph.D.

June 30, 2022
·
5 min read
·
Abbey Glasure
Research Roundup: Scientists Find Link Between COVID-19, New-Onset Diabetes

COVID-19 is much more than a respiratory illness, and many of its longer-term effects and secondary issues are often puzzling. For that and more research news, continue reading.

June 30, 2022
·
6 min read
·
Mark Terry
The Future of Healthcare: MIT, Bayer & Others Leverage AI, Machine Learning

From search engines to social media, algorithms are quickly becoming a part of everyday life, and companies like Bayer, MIT and others are using them to their advantage.

June 30, 2022
·
3 min read
·
Jazmine Colatriano, M.S.
Drug Development

Despite Threat of Omicron, World Shifts Focus Away from COVID-19

There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.

June 30, 2022
·
5 min read
·
Mark Terry
Big Pharma not Likely to Bail Out Battered Biotech Industry

The biotech industry has been looking for multiple sources of financing, and there has been speculation that big pharma might come to the rescue. But a recent report says that’s unlikely.

June 30, 2022
·
2 min read
·
Alex Keown
Business

AstraZeneca Touts China Expansion, Positive CHMP Opinions

AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe and a positive clinical trial update.

June 30, 2022
·
3 min read
·
Mark Terry
Drug Development

BeiGene, Lexicon and 9 Meters Wrap First Half with Clinical Wins

Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:

June 30, 2022
·
4 min read
·
Tristan Manalac
Business

Blueprint Draws Combined $1.25B Investment in Tough Market

Blueprint Medicines announced strategic financing collaborations with Sixth Street and Royalty Pharma for up to $1.25 billion to expand Blueprint’s pipeline and pursue business development opportunities.

June 30, 2022
·
3 min read
·
Hannah Chudleigh